140 related articles for article (PubMed ID: 2410068)
1. The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes.
Alter BP; Gilbert HS
Blood; 1985 Aug; 66(2):373-9. PubMed ID: 2410068
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
3. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
4. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Löfvenberg E; Wahlin A
Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
6. Effect of hydroxyurea on foetal haemoglobin in myeloproliferative & myelodysplastic syndromes.
Advani SH; Venugopal P; Charak BS; Das Gupta A; Mazumdar AT; Gopal R; Nair CN; Saikia TK; Nadkarni KS; Kurkure PA
Indian J Med Res; 1990 Apr; 92():83-5. PubMed ID: 1695200
[TBL] [Abstract][Full Text] [Related]
7. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
8. Cellular effects of hydroxyurea in Hb SC disease.
Steinberg MH; Nagel RL; Brugnara C
Br J Haematol; 1997 Sep; 98(4):838-44. PubMed ID: 9326175
[TBL] [Abstract][Full Text] [Related]
9. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Löfvenberg E; Nordenson I; Wahlin A
Cancer Genet Cytogenet; 1990 Oct; 49(1):57-67. PubMed ID: 2397474
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea and hemoglobin F in patients with myeloproliferative syndromes.
Alter BP; Gilbert HS
Prog Clin Biol Res; 1985; 191():455-61. PubMed ID: 2413481
[No Abstract] [Full Text] [Related]
12. Gangrene of the fingers secondary to myeloproliferative disease.
McDonald E; Marino C; Raftery T; Levine M
Postgrad Med; 1991 Jul; 90(1):115-8. PubMed ID: 2062751
[TBL] [Abstract][Full Text] [Related]
13. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and lower leg ulcers.
Nguyen TV; Margolis DJ
Cutis; 1993 Oct; 52(4):217-9. PubMed ID: 8261806
[TBL] [Abstract][Full Text] [Related]
16. Treatment of the myeloproliferative disorders with 32P.
Berlin NI
Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
[TBL] [Abstract][Full Text] [Related]
17. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Rukavitsyn OA; Pop VP; Seriakov AP
Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
19. Polycythaemia after myeloid metaplasia with fibrosis: an unusual sequence.
Gardais J; Suraniti S; Fressinaud P
Haematologica; 1992; 77(5):433-4. PubMed ID: 1483596
[TBL] [Abstract][Full Text] [Related]
20. Treatment of myeloproliferative diseases.
Sellei C
Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
